LncRNA MEG3: Targeting the Molecular Mechanisms and Pathogenic causes of Metabolic Diseases

Title:LncRNA MEG3: Targeting the Molecular Mechanisms and Pathogenic causes of Metabolic Diseases

Volume: 31 Issue: 37

Author(s): Yiyang Luo, Hailin Wang, Lijun Wang, Wei Wu, Jiale Zhao, Xueqing Li, Ruisi Xiong, Xueliang Ding, Ding Yuan and Chengfu Yuan*

Affiliation:

• Third-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China
• Department of Biochemistry, College of Basic Medical Science, China Three Gorges University, Yichang, 443002, China

Abstract:

Background: Non-coding RNA is a type of RNA that does not encode proteins, distributed among rRNA, tRNA, snRNA, snoRNA, microRNA and other RNAs with identified functions, where the Long non-coding RNA (lncRNA) displays a nucleotide length over 200. LncRNAs enable multiple biological processes in the human body, including cancer cell invasion and metastasis, apoptosis, cell autophagy, inflammation, etc. Recently, a growing body of studies has demonstrated the association of lncRNAs with obesity and obesity-induced insulin resistance and NAFLD, where MEG3 is related to glucose metabolism, such as insulin resistance. In addition, MEG3 has been demonstrated in the pathological processes of various cancers, such as mediating inflammation, cardiovascular disease, liver disease and other metabolic diseases.

Objective: To explore the regulatory role of lncRNA MEG3 in metabolic diseases. It provides new ideas for clinical treatment or experimental research.

Methods: In this paper, in order to obtain enough data, we integrate and analyze the data in the PubMed database.

Results: LncRNA MEG3 can regulate many metabolic diseases, such as insulin resistance, NAFLD, inflammation and so on.

Conclusion: LncRNA MEG3 has a regulatory role in a variety of metabolic diseases, which are currently difficult to be completely cured, and MEG3 is a potential target for the treatment of these diseases. Here, we review the role of lncRNA MEG3 in mechanisms of action and biological functions in human metabolic diseases.

Cite this article as:

Luo Yiyang, Wang Hailin, Wang Lijun, Wu Wei, Zhao Jiale, Li Xueqing, Xiong Ruisi, Ding Xueliang, Yuan Ding and Yuan Chengfu*, LncRNA MEG3: Targeting the Molecular Mechanisms and Pathogenic causes of Metabolic Diseases, Current Medicinal Chemistry 2024; 31 (37) . https://dx.doi.org/10.2174/0109298673268051231009075027